Alzheimer's Archives

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 27 May 2016

Biotech of the Week: Pharnext, developing next level drugs against Alzheimer’s and Parkinson’s disease

The Scandinavian charm is wonderful but this week we are (finally) heading back to Central Europe. Do I really need to say what happens in Paris? We all know that: The Eiffel Tower, the Louvre, the pretty sights, la Seine and it’s also the cité de l’amour. However, it is also where Pharnext, our Biotech of the Week, is […]

May 27, 2016 - 2 minutesmins - By Joachim Eeckhout

interview biotrinity labiotech dementia fund

News and Trends 28 Apr 2016

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London. The high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough. However, the need for […]

April 28, 2016 - 1 minutemin - By Philip Hemme

probiodrug alzheimers mark booth cbo e1458823157506

News and Trends 24 Mar 2016

Leading German Biotech recruits New talent for Fight against Alzheimer’s

Probiodrug (Germany) has hired Mark Booth as Chief Business Officer to propel this Pharma’s global strategy. Among other important roles, Booth was president of Takeda North America. Probiodrug is a Biopharma focused on developing treatments for Alzheimer’s disease. Its strategy is based on the elimination of pyroglutamated Abeta (pGlu), which is one of the way Alzheimer’s […]

March 24, 2016 - 2 minutesmins - By Denise Neves Gameiro

alzheimers dementia discovery fund takeda weizmann biogen rodin

News and Trends 25 Jan 2016

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea. The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October […]

January 25, 2016 - 3 minutesmins - By Dani Bancroft

biogen alzheimer proteros rodin therapeutics atlas neurology

News and Trends 8 Jan 2016

Epigenetics Baby of Proteros is Signing Up with Top US Neurology Specialists

Founded in just 2013 by German Proteros and the US Atlas Ventures, Rodin Therapeutics is working epigenetics into discovery of novel therapies for Neurological diseases. Now they have hooked one of the largest players in the field, Biogen, into a €446M partnership. Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin […]

January 8, 2016 - 3 minutesmins - By Dani Bancroft

probiodrug small molecule alzheimers disease trial

News and Trends 15 Dec 2015

Latest Small Molecule against Alzheimer’s Disease Success in Phase I Trials

Probiodrug‘s phase I tolerability and efficacy trial for Alzheimer’s didn’t quite go as planned, although results are in and it is still good news for this small molecule candidate. Probiodrug in Halle (Germany) is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s […]

December 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Dec 2015

Hydra’s Immortality is not Myth: Polyps Genetically Reprogram Skin Cells into Neurons

Relatives of the Jellyfish, researchers at the University of Geneva (Switzerland) have now proven the regenerative abilities of Hydra involved reprogramming cells. Does this have any implications for Neurodegenerative disease? Remember the Greek myth of Hydra? Amongst other twelve labours, Hercules had to slay the nine-headed monster Hydra which, in case nine jaws weren’t enough, […]

December 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 24 Nov 2015

2015 Review: What Exciting Developments Have Been Made in Neurodegenerative Disease?

Since both Alzheimer’s Disease and Parkinson’s combined affect up to 50 million people worldwide, it is no wonder this new wave of break-through milestones is getting the industry excited… The Central Nervous System (CNS) comprises many complex tissues and highly specialized cell types, mutation in which can cause an array of deadly and chronic diseases. […]

November 24, 2015 - 9 minutesmins - By Dani Bancroft

News and Trends 30 Oct 2015

Grifols takes a nice €100M slice for Alzheimer’s from EU €315 Billion Investment Offensive

A huge European action for the next three following years is the European Fund for Strategic Investments (aka the Juncker plan). This consists of a €315 billion Investment Plan to “get Europe growing and more people back to work” (as written on Europa’s website). The Barcelonan Grifols (Spain) is one of the first companies to receive its […]

October 30, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 10 Oct 2015

What Happened this Week? Nobel prize slips through CRISPR’s fingers, inside iGEM’s Jamboree and €120M boost for Alzheimer’s research

Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience at the iGEM Giant Boston Jamboree 2015 Wednesday: Sorry CRISPR, you’ll have to wait another year to win a Nobel Prize! Thursday: The Future Biotech Lab Bench: My experience of the cutting edge-tech at LABVOLUTION Friday: Alzheimer’s Disease: Phase III breakthrough Tau-therapy earns […]

October 10, 2015 - 1 minutemin - By Philip Hemme

News and Trends 9 Oct 2015

TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us